Attention Deficit Hyperactivity Disorder Treatment Practice in Turkey

Q Medicine

Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology Pub Date : 2016-11-08 DOI:10.5455/BCP.20151202103706

O. Oner, H. Türkçapar, F. Isli, H. Karadağ, A. Akbulat, A. Basci, M. Aksoy, Cem Seckin, A. Alkan

{"title":"Attention Deficit Hyperactivity Disorder Treatment Practice in Turkey","authors":"O. Oner, H. Türkçapar, F. Isli, H. Karadağ, A. Akbulat, A. Basci, M. Aksoy, Cem Seckin, A. Alkan","doi":"10.5455/BCP.20151202103706","DOIUrl":null,"url":null,"abstract":"ABSTRACTObjective: To determine the factors associated with type of ADHD prescription and re-admission of the cases to the outpatient clinics between January-July 2013.Method: The Ministry of Health prescription database, which included prescriber, region, age and gender data and contained almost 20% of IMS data.Results: A total of 73,189 prescription were prescribed to a total of 41,341 (30,014 males; 72.7%) patients. 38645 (93.5%) of the patients were between 6 and 18 years of age. The most frequently prescribed drug was OROS methylphenidate (MPH, 59.7%) followed by IR MPH, atomoxetine and combination of drugs. There were several regional differences in prescription practice. Treatment choice changed significantly with age and gender. Rate of repeated prescription was highest among 6–18 year-old male subjects receiving combination treatment.Conclusions: ADHD treatment choice seemed to be heavily influenced by official regulations. Age, gender and drug of choice were important factors associated with tre...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/BCP.20151202103706","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

ABSTRACTObjective: To determine the factors associated with type of ADHD prescription and re-admission of the cases to the outpatient clinics between January-July 2013.Method: The Ministry of Health prescription database, which included prescriber, region, age and gender data and contained almost 20% of IMS data.Results: A total of 73,189 prescription were prescribed to a total of 41,341 (30,014 males; 72.7%) patients. 38645 (93.5%) of the patients were between 6 and 18 years of age. The most frequently prescribed drug was OROS methylphenidate (MPH, 59.7%) followed by IR MPH, atomoxetine and combination of drugs. There were several regional differences in prescription practice. Treatment choice changed significantly with age and gender. Rate of repeated prescription was highest among 6–18 year-old male subjects receiving combination treatment.Conclusions: ADHD treatment choice seemed to be heavily influenced by official regulations. Age, gender and drug of choice were important factors associated with tre...

查看原文本刊更多论文

土耳其的注意缺陷多动障碍治疗实践

【摘要】目的:了解2013年1 - 7月ADHD处方类型与门诊再入院的相关因素。方法:卫生部处方数据库，包括处方者、地区、年龄和性别数据，包含近20%的IMS数据。结果:共开处方73,189张，共41,341例(男性30,014例;72.7%)患者。38645例(93.5%)患者年龄在6 ~ 18岁。最常见的处方药物是哌甲酯OROS (MPH, 59.7%)，其次是IR MPH、托莫西汀和联合用药。在处方实践中存在一些地区差异。治疗选择随年龄和性别的变化显著。重复处方率以6 ~ 18岁男性联合用药者最高。结论:ADHD的治疗选择似乎受到官方规定的严重影响。年龄、性别和药物选择是与三种药物相关的重要因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology 医学-精神病学

CiteScore

0.34

自引率

0.00%

发文量

审稿时长

6-12 weeks